603669.SH
灵康药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.39
−1.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 358.9M | 322.5M | 379.8M | 196.8M | 289.3M |
| Cost of Revenue | 207.0M | 181.5M | 201.7M | 105.0M | 93.1M |
| Gross Profit | 151.9M | 141.0M | 178.0M | 91.9M | 196.1M |
| Operating Expenses | |||||
| R&D Expense | 10.9M | 12.7M | 26.7M | 29.1M | 31.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 71.0M | 74.6M | 89.5M | 93.8M | 90.9M |
| Selling & Marketing Expense | 155.0M | 154.8M | 142.0M | 120.3M | 236.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 304.6M | 309.0M | 264.6M | 248.8M | 364.3M |
| Cost and Expenses | 511.6M | 490.6M | 466.4M | 353.8M | 457.4M |
| Operating Income (EBIT) | (174.6M) | (196.0M) | (128.8M) | (149.0M) | (188.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (171.6M) | (193.5M) | (127.7M) | (151.0M) | (188.8M) |
| Income Tax Expense | 39.2K | (275.1K) | 3.0M | 540.8K | 7.1M |
| Bottom Line | |||||
| Net Income | (171.7M) | (193.2M) | (130.8M) | (151.5M) | (195.9M) |
| Earnings from Cont. Ops | (171.7M) | (193.2M) | (130.8M) | (151.5M) | (195.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (171.7M) | (193.2M) | (130.8M) | (151.5M) | (195.9M) |
| Per Share | |||||
| Basic EPS | (CN¥0.24) | (CN¥0.27) | (CN¥0.18) | (CN¥0.21) | (CN¥0.27) |
| Diluted EPS | (CN¥0.24) | (CN¥0.27) | (CN¥0.18) | (CN¥0.21) | (CN¥0.27) |
| Revenue Per Share | CN¥0.50 | CN¥0.45 | CN¥0.52 | CN¥0.27 | CN¥0.40 |
| Shares | |||||
| Basic Shares Outstanding | 721.0M | 715.7M | 726.5M | 721.4M | 725.4M |
| Diluted Shares Outstanding | 721.0M | 715.7M | 726.5M | 721.4M | 725.4M |
| Profitability Metrics | |||||
| EBITDA | — | (161.4M) | (91.3M) | (101.2M) | (141.4M) |
| D&A | — | 34.6M | 37.5M | 47.8M | 47.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026